Sign In
Buy BCDA
$0.87
-0.0256 (-2.84%)
At Close: Jun 03, 2026
How Much Is BioCardia, Inc. (NASDAQ:BCDA) Paying Its CEO?
10:51am, Wednesday, 22'nd Jul 2020
Peter Altman became the CEO of BioCardia, Inc. (NASDAQ:BCDA) in 2002, and we think it's a good time to look at the...
I-Mab (NASDAQ:BDTX) and BioCardia (NASDAQ:BCDA) Financial Survey
02:04am, Tuesday, 07'th Jul 2020
I-Mab (NASDAQ:BDTX) and BioCardia (OTCMKTS:BCDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, divi
BioCardia Announces Activation of Pivotal Trial Studying CardiAMP Cell Therapy Trial to Treat Chronic Myocardial Ischemia
02:20pm, Wednesday, 01'st Jul 2020
The purpose of the study is to determine the safety and efficacy of CardiAMP cell therapy in the treatment of patients with refractory angina pectoris and CMI. The FDA has said that the trial qualifi
BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era
12:00pm, Wednesday, 01'st Jul 2020
SAN CARLOS, Calif., July 01, 2020 -- BioCardia®, Inc., (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
BioCardia Announces CardiAMP Heart Failure Pivotal Trial Continues with First Patient Randomized in COVID-19 Era
12:00pm, Monday, 29'th Jun 2020
BioCardia®, Inc., (BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Company has resumed cases in the CardiAMP Heart Fa
Reviewing Rubius Therapeutics (NASDAQ:RUBY) & BioCardia (NASDAQ:BCDA)
07:26am, Sunday, 28'th Jun 2020
Rubius Therapeutics (NASDAQ:RUBY) and BioCardia (OTCMKTS:BCDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their e
BioCardia (OTCMKTS:BCDA) Shares Gap Down to $2.12
05:54am, Saturday, 20'th Jun 2020
BioCardia Inc (OTCMKTS:BCDA) gapped down prior to trading on Thursday . The stock had previously closed at $2.20, but opened at $2.12. BioCardia shares last traded at $2.22, with a volume of 501,462 s
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
12:00am, Thursday, 18'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)
Adverum Biotechnologies Inc...
BioCardia Announces Pricing of $10 Million Public Offering
12:30pm, Wednesday, 17'th Jun 2020
BioCardia®, Inc. NasdaqCM: BCDA (the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the pricing of its public offer
Vivet Therapeutics meldete heute, dass sowohl die US-Food and Drug Administration (FDA) als auch die Europäische Kommission (EC) VTX-803, das zweite G
BioCardia Reports First Quarter 2020 Financial Results and Business Highlights
12:00pm, Friday, 15'th May 2020
SAN CARLOS, Calif., May 15, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering
05:40pm, Tuesday, 12'th May 2020
This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.
SAN CARLOS, Calif., May 05, 2020 -- BioCardia®, Inc. , a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today.
BioCardia (BCDA) Gets a Buy Rating from Maxim Group
04:56pm, Friday, 01'st May 2020
In a report released today, Jason McCarthy from Maxim Group assigned a Buy rating to BioCardia (BCDA), with a price target of $9.00. The company's shares
